Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Braz. j. med. biol. res ; 50(10): e6363, 2017. tab
Artículo en Inglés | LILACS | ID: biblio-888933

RESUMEN

This study aimed to test the effects of xuezhikang, a cholestin extract that contains statin-like components, on arterial stiffness in patients with essential hypertension. One hundred hypertensive patients from the Chinese PLA General Hospital were randomly allocated to receive xuezhikang (1200 mg/day, orally) or placebo (same capsules containing only pharmaceutical excipients). Physical examination outcomes, lipid profile, high sensitivity C-reactive protein (hs-CRP) levels, matrix metalloproteinases-9 (MMP-9) levels, and arterial outcomes, including stiffness parameter (β), pressure-strain elasticity modulus (Ep), arterial compliance (AC), augmentation index (AI), and one-point pulse wave velocity (PWVβ) were obtained at baseline and after 6 months of the intervention. Xuezhikang significantly reduced β (8.4±3.1 vs 6.8±2.1, P=0.007), Ep (122.8±43.9 vs 100.7±33.2, P=0.009), PWVβ (6.7±1.2 vs 6.1±1.0, P=0.013), low-density lipoprotein cholesterol (3.4±0.6 vs 2.9±0.5, P=0.001), hs-CRP [2.1 (0.4-10.0) vs 1.4 (0.3-4.1), P=0.020], and MMP-9 (17.2±2.4 vs 12.7±3.8, P <0.001) compared to baseline. The placebo had no effect on these parameters. The changes of PWVβ in the xuezhikang group was significantly associated with the changes of hs-CRP and MMP-9 (r=0.144, P=0.043; r=0.278, P=0.030, respectively) but not with lipid profile changes. Our research showed xuezhikang can improve the parameters of arterial stiffness in hypertensive patients, and its effect was independent of lipid lowering.


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Medicamentos Herbarios Chinos/uso terapéutico , Hipertensión Esencial/tratamiento farmacológico , Rigidez Vascular/efectos de los fármacos , Medicamentos Herbarios Chinos/efectos adversos , Hipertensión Esencial/sangre , Hipertensión Esencial/fisiopatología , Lípidos/sangre , Análisis de la Onda del Pulso , Rigidez Vascular/fisiología
2.
Braz. j. med. biol. res ; 49(4): e4324, 2016. tab, graf
Artículo en Inglés | LILACS | ID: biblio-951663

RESUMEN

The effects of interleukin-10 (IL-10) and glucose on mRNA and protein expression of osteoprotegerin (OPG), and its ligand, receptor activator of nuclear factor-κB ligand (RANKL), were investigated in human periodontal ligament fibroblasts (HPDLFs). Primary HPDLFs were treated with different concentrations of IL-10 (0, 1, 10, 25, 50, and 100 ng/mL) or glucose (0, 5.5, 10, 20, 30, and 40 mmol/L). Changes in mRNA and protein expression were examined using the reverse-transcription polymerase chain reaction (RT-PCR) and Western blot analysis, respectively. After IL-10 treatment, mRNA and protein levels of OPG were increased, while mRNA and protein levels of RANKL were decreased (P<0.05), both in a concentration-dependent manner. Glucose stimulation had the opposite concentration-dependent effect to that of IL-10 on OPG and RANKL expression. IL-10 upregulated OPG expression and downregulated RANKL expression, whereas high glucose upregulated RANKL and downregulated OPG in HDPLFs. Abnormal levels of IL-10 and glucose may contribute to the pathogenesis of periodontal disease.


Asunto(s)
Humanos , Ligamento Periodontal/efectos de los fármacos , Interleucina-10/farmacología , Ligando RANK/metabolismo , Osteoprotegerina/metabolismo , Fibroblastos/efectos de los fármacos , Glucosa/farmacología , Ligamento Periodontal/citología , Factores de Tiempo , ARN Mensajero/análisis , Regulación hacia Abajo , Regulación hacia Arriba , Células Cultivadas , Western Blotting , Análisis de Varianza , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Fibroblastos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA